New global study discovers people in pain feel more socially excluded than ever
28 sept. 2023 04h00 HE
|
Haleon
Latest edition of Haleon Pain Index finds half (49%) of people in pain feel stigmatised[1][2]42% regularly feel lonely due to their pain, and one third feel serious loneliness (based on UCLA...
AlgoTx Announces First Patients Dosed in US and European Arms of Phase II Clinical Trial of ATX01 in Rare Disease Erythromelalgia
12 sept. 2023 03h00 HE
|
AlgoTX
PARIS, Sept. 12, 2023 (GLOBE NEWSWIRE) -- AlgoTherapeutix (AlgoTx), a clinical stage biotechnology company developing targeted, first-in-class therapeutics for peripheral neuropathic pain,...
PETVIVO HOLDINGS, INC. ANNOUNCES PARTICIPATION AT THE H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE SEPTEMBER 11-13, 2023
05 sept. 2023 08h00 HE
|
PetVivo Holdings, Inc.
MINNEAPOLIS, Sept. 05, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo"), an emerging biomedical device company focused on the commercialization of innovative...
PetVivo Holdings, Inc. Achieves National Distribution of Spryng to More than 500 Veterinary Clinics in 49 States
28 août 2023 08h00 HE
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, US, Aug. 28, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company"), an emerging biomedical device company focused on the commercialization of...
PetVivo Recieves Notice of Allowance from United States Patent and Trademark Office for Key Patent Application
17 août 2023 08h00 HE
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, Aug. 17, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of...
PetVivo Reports First Quarter of Fiscal 2024 Financial Results
10 août 2023 16h00 HE
|
PetVivo Holdings, Inc.
Conference call begins at 4:00 p.m. Central time today EDINA, MN, Aug. 10, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (Nasdaq: PETV and PETVW), an emerging biomedical device company focused...
PETVIVO HOLDINGS, INC. TO ANNOUNCE RESULTS FOR THE FIRST QUARTER ENDED June 3, 2023
07 août 2023 13h50 HE
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, US, Aug. 07, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV and PETVW), an emerging biomedical device company focused on the commercialization of innovative medical...
OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (“NCP”) Following Announcement of Clinical Trial Agreement with Tufts Medical Center
28 juil. 2023 07h01 HE
|
OKYO Pharma LTD
OKYO plans a 40-patient OK-101 open-label clinical trial with Dr Pedram Hamrah, Tufts Medical Center, as Principal Investigator, a leading expert in treating patients with NCPSecond clinical...
PetVivo Holdings, Inc. Achieves National Distribution of Spryng to More than 450 Veterinary Clinics
20 juil. 2023 08h20 HE
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, US, July 20, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of...
Incannex Receives HREC Approval for Phase 2 Clinical Trial Assessing IHL-675A for use in Treatment of Pain and Function in Rheumatoid Arthritis
13 juil. 2023 08h00 HE
|
Incannex Healthcare
Highlights: Incannex has received approval from HREC for the lead site, Emeritus Research, Camberwell, VIC for the Phase 2, Blinded, Placebo Controlled Clinical Trial to Determine the Effect on Pain...